Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

This Study Will Evaluate if the Field Force Pulsed Field Ablation System is Safe and Effective for Treating Sustained Monomorphic Ventricular Tachycardia, a Potentially Serious Fast Heart Rhythm of the Heart. The Treatment Uses Short Pulses of Energy to Target and Destroy the Heart Tissue Causing VT

14. September 2026 aktualisiert von: Field Medical

Pivotal Study to Evaluate Catheter Ablation in Patients With Scar-Related Monomorphic Sustained VT in the Ventricular Ectopy and Reduction in Tachycardia Ablation Studies Program (VERITAS SCAR VT)

The VERITAS VT Study is a prospective, multicenter, international, single-arm clinical investigation designed to evaluate the safety and effectiveness of the FieldForce™ Pulsed Field Ablation System for the treatment of sustained monomorphic ventricular tachycardia (VT). Eligible patients undergoing catheter ablation for VT will receive treatment with the investigational pulsed field ablation system according to the study protocol.

The study will assess acute and chronic outcomes including major adverse events, freedom from recurrent ventricular tachycardia, need for antiarrhythmic drug escalation, repeat ablation procedures, and other clinically relevant outcomes through 180 days following the index ablation procedure.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Ventricular tachycardia remains a significant source of morbidity and mortality among patients with structural heart disease. Although catheter ablation is an established therapeutic option, long-term recurrence rates remain substantial and procedural challenges continue to exist.

The VERITAS VT Study is a prospective, multicenter, single-arm clinical investigation evaluating the safety and effectiveness of the Field Force Pulsed Field Ablation System in subjects with sustained monomorphic ventricular tachycardia. Eligible participants will undergo mapping and ablation using the Field Force Pulsed Field Ablation System during the index procedure. Subjects will be followed for 180 days after the index procedure to assess safety and effectiveness outcomes.

The primary safety objective is to evaluate the incidence of device- and procedure-related major adverse events. The primary effectiveness objective is to evaluate freedom from recurrence of sustained monomorphic ventricular tachycardia through 180 days following the index ablation procedure

Studientyp

Interventionell

Einschreibung (Geschätzt)

180

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  1. Signed patient informed consent form (ICF).
  2. Female and male patients aged ≥ 18 and ≤ 85 years.
  3. Implantable Cardioverter-Defibrillator (ICD) implanted ≥ 180 days prior to enrollment.
  4. Clinically Indicated for ventricular tachycardia (VT) ablation by 2019 guidelines:

    • At least one (1) episode of VT, defined as continuous VT lasting > 30 seconds or requiring termination due to hemodynamic compromise, detected by an implanted ICD ≤ 180 days prior to enrollment and
    • Refractory to, contraindicated or intolerant of at least one (1) Class I or III Antiarrhythmic Drug (AAD)
  5. Sustained scar-related monomorphic ventricular tachycardia (MMVT):

    • Objective evidence of ventricular scar confirmed by imaging (magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), intracardiac echocardiography/ transesophageal echocardiogram (ICE/TEE) and/or electro anatomical mapping (EAM)) Or
    • Prior myocardial infarction (MI)
  6. Left ventricular ejection fraction (LVEF) ≥ 20% confirmed by echocardiography or comparable imaging techniques within 180 days prior to enrollment or during baseline evaluation.

Exclusion Criteria:

Subjects will be excluded if ANY of the following apply:

  1. VT secondary to reversible causes (e.g. electrolyte abnormalities, drug or alcohol-induced arrhythmia or non-cardiac cause).
  2. VT ablation within 14 days prior to enrollment.
  3. Greater than three (3) VT ablations within one (1) year prior to enrollment.
  4. Ventricular fibrillation (VF), polymorphic VT or Torsades de Pointes (TdP) as primary clinical arrhythmia.
  5. Bundle branch reentry (BBR), Idiopathic, Para-Hisian or Fascicular VT.
  6. For non-ischemic cardiomyopathy (NICM) if the following apply:

    • Active (within 120 days) inflammatory process (e.g. myocarditis)
    • Sarcoidosis
    • Hypertrophic cardiomyopathy (HCM)
    • Laminopathy (LMNA-related cardiomyopathy)
    • Brugada syndrome (BrS)
    • Amyloidosis
  7. Acute myocardial infarction ≤ 90 days prior to enrollment.
  8. Recent cardiac intervention ≤ 90 days prior to enrollment including but not limited to Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft (CABG), lead revision or upgrade, etc.
  9. Implanted with a ventricular assist device (VAD).
  10. Severe mitral or aortic regurgitation or stenosis evaluated by echo or comparable technique.
  11. Presence of an aortic or mitral mechanical valve.
  12. New York Heart Association (NYHA) Class IV heart failure.
  13. Uncontrolled abnormal bleeding and/or clotting disorder.
  14. Contraindication to systemic or oral anticoagulation.
  15. Presence of active intracardiac thrombus detected by imaging (pre-procedural via transesophageal echocardiogram (TEE) or transthoracic echocardiogram (TTE), CT, MRI, or intra-procedural via intracardiac echocardiography (ICE).
  16. Ineligible for ablation according to physician judgement (including but not limited to hemodynamically unstable, prior interatrial patch, Amplatzer, etc.).
  17. Serious or untreated medical conditions that would prevent participation in the study interfere with assessment or therapy, or confound data or its interpretation, including but not limited to solid organ or hematologic transplant, or currently being evaluated for an organ transplant.
  18. Severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gases or significant dyspnea at the time of enrollment.
  19. Body Mass Index ≥ 40.
  20. Chronic renal insufficiency of estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2.
  21. Active malignancy.
  22. Active systemic infection.
  23. Life expectancy is less than one year.
  24. Prohibitively distorted cardiac anatomy due to congenital heart disease.
  25. Participation in another investigational study that may interfere with the procedure outcomes for this study unless pre-approved by sponsor.
  26. Unable to understand the nature of this study or is unwilling or unable to attend all the study visits.
  27. Pregnancy or planned pregnancy, lactating or any women of childbearing potential who is not on a reliable form of birth control.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Field Force Pulsed Fiel Ablation
Participants will undergo ventricular tachycardia ablation using the Field Force Pulsed Field Ablation System during the index procedure.
The Field Force Pulsed Field Ablation System is an investigational device that delivers non-thermal pulsed electric field energy through a catheter-based platform to ablate targeted cardiac tissue. The system is intended for use during catheter ablation procedures in patients with sustained monomorphic ventricular tachycardia (VT) to treat tissue involved in the initiation and maintenance of the arrhythmia.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Primary Safety Endpoint - Freedom from casual or probable device or procedure related Major Adverse Events (MAEs) that occur within 7 days following the ablation procedure. (Or within 90 days for esophageal events (fistula/perforation)
Zeitfenster: As applicable within 7 days or 90 days after the index ablation procedure
A pre-defined list of device - or procedure-related MAEs, as adjudicated by the Clinical Events Committee (CEC), occurring within 7 days after the index ablation procedure (or within 3 months after the index ablation procedure for any esophago-pericardial fistula/esophageal perforation) will be considered a primary safety event
As applicable within 7 days or 90 days after the index ablation procedure
Primary Effectiveness: Freedom from recurrence of sustained monomorphic VT
Zeitfenster: Through 6 months most the index ablation procedure
Freedom from recurrence of sustained monomorphic VT (MMVT) in the absence of new or increased dose of Class I or III antiarrhythmic drugs (AAD) for any ventricular arrhythmia through 6 months after the index ablation procedure
Through 6 months most the index ablation procedure

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Secondary Effectiveness Endpoint: Percentage of patients with reduced ventricular tachycardia burden
Zeitfenster: 6 months post index procedure
Percentage of patients with reduced ventricular tachycardia burden
6 months post index procedure

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Vivek Reddy, MD, Mount Sinai Hospital

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Dezember 2026

Primärer Abschluss (Geschätzt)

1. August 2027

Studienabschluss (Geschätzt)

1. Februar 2028

Studienanmeldedaten

Zuerst eingereicht

26. August 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

26. August 2026

Zuerst gepostet (Tatsächlich)

31. August 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

14. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • CLN-00011

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .